White matter hyperintensities are higher among early-onset Alzheimer's disease participants than their cognitively normal and early-onset nonAD peers: Longitudinal Early-onset Alzheimer's Disease Study (LEADS).
Alzheimer's disease
EOAD
WMH
amyloid
tau PET
tau positron emission tomography
white matter hyperintensities
Journal
Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
revised:
23
05
2023
received:
03
03
2023
accepted:
24
05
2023
medline:
30
11
2023
pubmed:
26
7
2023
entrez:
26
7
2023
Statut:
ppublish
Résumé
We compared white matter hyperintensities (WMHs) in early-onset Alzheimer's disease (EOAD) with cognitively normal (CN) and early-onset amyloid-negative cognitively impaired (EOnonAD) groups in the Longitudinal Early-Onset Alzheimer's Disease Study. We investigated the role of increased WMH in cognition and amyloid and tau burden. We compared WMH burden of 205 EOAD, 68 EOnonAD, and 89 CN participants in lobar regions using t-tests and analyses of covariance. Linear regression analyses were used to investigate the association between WMH and cognitive impairment and that between amyloid and tau burden. EOAD showed greater WMHs compared with CN and EOnonAD participants across all regions with no significant differences between CN and EOnonAD groups. Greater WMHs were associated with worse cognition. Tau burden was positively associated with WMH burden in the EOAD group. EOAD consistently showed higher WMH volumes. Overall, greater WMHs were associated with worse cognition and higher tau burden in EOAD. This study represents a comprehensive characterization of WMHs in sporadic EOAD. WMH volumes are associated with tau burden from positron emission tomography (PET) in EOAD, suggesting WMHs are correlated with increasing burden of AD. Greater WMH volumes are associated with worse performance on global cognitive tests. EOAD participants have higher WMH volumes compared with CN and early-onset amyloid-negative cognitively impaired (EOnonAD) groups across all brain regions.
Substances chimiques
Amyloid beta-Peptides
0
tau Proteins
0
Amyloidogenic Proteins
0
Amyloid
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
S89-S97Subventions
Organisme : NIA NIH HHS
ID : U01 AG057195
Pays : United States
Organisme : NIA NIH HHS
ID : R56 AG057195
Pays : United States
Organisme : NIA NIH HHS
ID : R56 AG057195
Pays : United States
Organisme : Alzheimer's Association
ID : LEADSGENETICS-19-639372
Pays : United States
Organisme : Alzheimer's Association
ID : LDRFP-21-824473
Pays : United States
Organisme : Alzheimer's Association
ID : LDRFP-21-828356
Pays : United States
Informations de copyright
© 2023 the Alzheimer's Association.
Références
Yoshita M, Fletcher E, Harvey D, et al. Extent and distribution of white matter hyperintensities in normal aging, MCI, and AD. Neurology. 2006;67(12):2192-2198.
Lee S, Viqar F, Zimmerman ME, et al. White matter hyperintensities are a core feature of Alzheimer's disease: evidence from the dominantly inherited Alzheimer network. Ann Neurol. 2016;79(6):929-939.
Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69(24):2197-2204.
Schoemaker D, Zanon Zotin MC, Chen K, et al. White matter hyperintensities are a prominent feature of autosomal dominant Alzheimer's disease that emerge prior to dementia. Alzheimers Res Ther. 2022;14(1):1-11. 2022.
Lee S, Zimmerman ME, Narkhede A, et al. White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimer's disease. PLoS One. 2018;13(5):e0195838.
Graff-Radford J, Arenaza-Urquijo EM, Knopman DS, et al. White matter hyperintensities: relationship to amyloid and tau burden. Brain. 2019;142(8):2483-2491.
Laing KK, Simoes S, Baena-Caldas GP, et al. Cerebrovascular disease promotes tau pathology in Alzheimer's disease. Brain commun. 2020;2(2):fcaa132.
Hopkins RO, Beck CJ, Burnett DL, Weaver LK, Victoroff J, Bigler ED. Prevalence of white matter hyperintensities in a young healthy population. J Neuroimaging. 2006;16(3):243-251.
Mao C, Li J, Huang X, et al. White matter hyperintensities and patterns of atrophy in early onset Alzheimer's disease with causative gene mutations. Clin Neurol Neurosurg. 2021;203:106552.
Apostolova LG, Aisen P, Eloyan A, et al. The longitudinal early-onset Alzheimer's disease study (LEADS): framework and methodology. Alzheimers Dement. 2021;17(12):2043-2055.
Raghavan S, Reid RI, Przybelski SA, et al. Diffusion models reveal white matter microstructural changes with ageing, pathology and cognition. Brain commun. 2021;3(2):fcab106.
Wardlaw JM, Chappell FM, Hernández MDCV, et al. White matter hyperintensity reduction and outcomes after minor stroke. Neurology. 2017;89(10):1003-1010.
Gaubert M, Lange C, Garnier-Crussard A, et al. Topographic patterns of white matter hyperintensities are associated with multimodal neuroimaging biomarkers of Alzheimer's disease. Alzheimers Res Ther. 2021;13(1):1-11.
Hu HY, Ou YN, Shen XN, et al. White matter hyperintensities and risks of cognitive impairment and dementia: a systematic review and meta-analysis of 36 prospective studies. Neurosci Biobehav Rev. 2021;120:16-27.
Desmarais P, Gao AF, Lanctôt K, et al. White matter hyperintensities in autopsy-confirmed frontotemporal lobar degeneration and Alzheimer's disease. Alzheimers Res Ther. 2021;13(1):1-16.
McAleese KE, Walker L, Graham S, et al. Parietal white matter lesions in Alzheimer's disease are associated with cortical neurodegenerative pathology, but not with small vessel disease. Acta Neuropathol. 2017;134(3):459-473.
Caroli A, Frisoni GB. Alzheimer's disease neuroimaging initiative the dynamics of Alzheimer's disease biomarkers in the Alzheimer's disease neuroimaging initiative cohort. Neurobiol Aging. 2010;31:1263-1274.